ICT-01 is under clinical development by ImCheck Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ICT-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ICT-01 overview

ICT-01 is under development for the treatment of relapsed and refractory solid tumors including bladder cancer, breast cancer, colon cancer, gastric cancer, melanoma, ovarian cancer, prostate cancer, colorectal cancer, pancreatic cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer, metastatic colorectal cancer, metastatic ovarian cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer and relapsed and refractory hematologic malignancies including acute myeloid leukemia, acute lymphocytic leukemia, Diffuse large B cell lymphoma, pancreatic ductal adenocarcinoma and follicular lymphoma. The drug candidate acts by targeting butyrophilin subfamily 3 (BTN3) and activating gamma delta T cells.

ImCheck Therapeutics overview

ImCheck Therapeutics is a biotechnology company that designs and develops novel immunotherapeutics. The company’s pipeline products include ICT01, ICTXX and ICT03 treat cancer; ICT41 treats infectious diseases; and ICT21 is a BTN3A antagonist that treats autoimmune diseases. It’s ICT01 and ICT41 is a humanized anti-BTN3A monoclonal antibody that selectively activates ?9d2 T cells. The company works in collaboration with institutions and academics to develop precision and personalized medicines. ImCheck Therapeutics is headquartered in Marseille, France.

For a complete picture of ICT-01’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.